GSK vs MAZE · P/E 13, $103.31B cap vs rev $20.0M
GlaxoSmithKline PLC ADR (GSK) versus Maze Therapeutics, Inc. Common Stock (MAZE) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported MAZE revenue for 2026-06-30 was $20.0M. Net income was -$68.9M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. MAZE currently screens at market cap $525.3M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. MAZE currently screens at market cap $525.3M.
Not investment advice. Open the GSK and MAZE stock pages for the full models.
Not investment advice.